Overview

Detailed Summary

Sanjivani Paranteral Limited is a WHO‑GMP certified Indian pharmaceutical manufacturer focused on sterile injectables and oral solid dosage forms, exporting to over 25 countries and operating manufacturing facilities in Navi Mumbai, Dehradun, Pune (SPL Infusion) and Prague (Alevia JV) while serving hospital and distributor channels in emerging markets.
Q3 FY26 performance was robust: standalone revenue of INR208.6 million (up 20.3% YoY), EBITDA of INR38.8 million (up 35.7% YoY) and PAT of INR26.2 million (up 37.8% YoY), with exports contributing roughly 77% of revenue and consolidated numbers showing slightly stronger YoY growth driven by new subsidiaries.
Margins tell a mixed story: gross margin compressed materially year‑on‑year due to higher COGS while EBITDA margin expanded to 18.4% driven by favourable product mix and lower other expenses, indicating the company can protect operating profitability through mix and cost control despite input cost pressure.
The company is transitioning to a multi‑vertical platform — Pune infusion facility has started contributing commercially and Prague nutraceutical JV has begun commercial batches — and management is guiding a material revenue step‑up in FY27, supported by product portfolio expansion and strategic partnerships.

Sector: Pharmaceuticals & Biotechnology
Industry: Pharmaceuticals
Market Cap: 186 Cr
Volatility: Moderate Risk
P/E Ratio: 27.7
Industry P/E: 33.7
PEG Ratio: 1.4
P/B Ratio: 3.8
52W High: 268.80
52W Low: 126.00

Sales CAGR

1Y: 28.84%
3Y: 31.81%
5Y: 33.78%
10Y: -5.40%

Profit CAGR

1Y: 31.12%
3Y: 18.68%
5Y: —
10Y: —

ROE

TTM: 13.87%
3Y: 29.89%
5Y: 241.93%
10Y: 55.97%

ROCE

TTM: 16.29%
3Y: 33.21%
5Y: 100.46%
10Y: 85.29%

Technicals

‌

Forecasts

Peers

Healthcare Healthcare Pharmaceuticals

Symbol	Watchlist	Price	Market Cap	P/E	P/B	Div Yield (%)	ROE (%)	ROCE (%)	ROA (%)
BROOKS		66.50	195 Cr	7.95	1.59	0.00	20.04	19.30	16.59
SPML		214.10	188 Cr	14.44	2.64	0.00	18.31	18.42	13.68
OXYGENTAPH		50.19	186 Cr	-10.57	0.00	0.00	41.16	-26.02	-14.69
ANL		255.10	185 Cr	36.79	6.02	0.00	14.29	16.99	12.01
SANJIVIN		149.60	181 Cr	27.02	3.75	0.00	13.87	16.29	7.62
CORALAB		502.50	177 Cr	10.83	0.85	0.00	7.83	10.89	6.81
GUJINJEC		119.90	176 Cr	96.51	14.84	0.00	15.34	21.17	4.96
Median: 7 Co.	—	149.60	185 Cr	14.44	2.64	0.00	15.34	16.99	7.62

Financial Statements

AI Powered Summary

Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.

Ask AI

Consolidated Quarterly Results (in ₹ Crores)

View Standalone

Total Figures

QoQ Changes

Total Figures

	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Sales	15	13	16	18	17	18	18	16	22	13
Expenses	13	11	14	15	15	16	15	13	18	12
Operating Profit	1.96	2.16	2.34	2.86	2.55	2.61	2.64	2.25	3.84	1.58
OPM %	13.10	16.80	14.23	15.77	14.70	14.36	14.76	14.52	17.41	11.96
Other Income	0.25	0.05	0.09	0.39	0.31	0.43	0.04	0.16	0.30	0.60
Interest	0.08	0.09	0.02	0.18	0.19	0.20	0.22	0.05	0.21	0.31
Depreciation	0.24	0.24	0.13	0.15	0.16	0.18	0.16	0.17	0.23	0.66
Profit Before Tax	1.90	1.88	2.27	2.92	2.51	2.65	2.30	2.19	3.70	1.20
Tax %	13.16	33.51	24.67	21.23	24.30	17.74	24.78	25.11	24.86	54.17
Net Profit	1.65	1.26	1.71	2.30	1.90	2.19	1.73	1.64	2.78	0.55
EPS in Rs	1.34	1.03	1.40	1.86	1.54	1.56	1.36	1.33	2.21	0.49

Consolidated Profit Loss (in ₹ Crores)

View Standalone

Total Figures

YoY Changes

Total Figures

	Mar 2024	Mar 2025
Sales	54	70
Expenses	46	60
Operating Profit	8.24	10
OPM %	15.15	14.77
Other Income	0.52	1.21
Interest	0.25	0.59
Depreciation	0.93	0.62
Profit Before Tax	7.57	10
Tax %	18.58	21.81
Net Profit	6.17	8.09
EPS in Rs	—	6.36
Dividend Payout %	0.00	0.00

Consolidated Balance Sheet (in ₹ Crores)

View Standalone

Total Figures

YoY Changes

Total Figures

	Mar 2024	Mar 2025
Equity Capital	12	12
Reserves	16	26
Borrowings	0.97	8.14
Other Liabilities	15	32
Total Liabilities	43	78
Fixed Assets	9.94	21
CWIP	0.00	19
Investments	0.00	0.00
Other Assets	33	38
Total Assets	43	78

Consolidated Cash Flows (in ₹ Crores)

View Standalone

Total Figures

YoY Changes

Total Figures

	Mar 2024	Mar 2025
Cash from Operating Activity	-11	12
Cash from Investing Activity	-12	-22
Cash from Financing Activity	23	10
Net Cash Flow	0.24	0.94

Shareholdings

Shareholding History

Quarterly

Yearly

Quarterly

	Sep 2023	Dec 2023	Feb 2024	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Promoters	32.34%	32.34%	27.67%	27.67%	27.67%	27.67%	27.67%	28.87%	28.87%	31.20%	31.20%	31.26%
FIIs	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
DIIs	8.16%	6.01%	10.21%	9.70%	9.36%	6.25%	6.25%	6.15%	6.15%	6.03%	6.04%	6.04%
Public	59.50%	61.65%	62.12%	62.63%	62.97%	66.08%	66.08%	64.98%	64.98%	62.77%	62.76%	62.71%
Total Shareholders	4,500	4,499	4,800	4,911	6,166	6,731	6,618	6,447	6,429	6,307	6,017	5,933

Market Transactions

Unlock more with professional

Real-time bulk & block deal transactions
Export transaction data for analysis

Projection

Documents

Presentations

Concalls

Reports

Presentations

Investor Presentation

Q4 FY26

Investor Presentation

Q3 FY26

Investor Presentation

Q2 FY26

Available on Pro Plan